Sunscreen Rule Will Cost Four Times FDA’s Prediction, Industry Tells OMB
This article was originally published in The Tan Sheet
Executive Summary
FDA's low-ball estimate of the cost to industry from the final OTC sunscreen monograph – a quarter of the amount manufacturers anticipate – relieved the agency from having to submit a full account of its rulemaking to the Office of Management and Budget, Energizer Holdings suggests.
You may also be interested in...
Industry Groups Shine Light On “Helps Prevent” Claim In Sunscreen Comments
Sunscreen labeling that claims the product "helps prevent" premature skin aging, cancer and other damage does not suggest sunscreen alone protects against these conditions, but in fact informs consumers that "complementary measures" are needed for adequate protection, according to trade groups' comments on FDA's proposal to amend the sunscreen final monograph
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.
MoCRA Implementation In US Election Year: Q&A With Attorney Wade Ackerman
Wade Ackerman, partner at Covington & Burling who served previously as senior FDA counsel to US Senate Health Education, Labor & Pensions (HELP) Committee leadership, discusses expectations for FDA activity under modernized cosmetics regulations in 2024.